JAK1 and neoplasm: Using JAK1/2-KOs cell lines we showed that intratumoral administration of the TLR-9 agonist SD-101 was able to overcome local resistance to anti-PD-1 even in abscopal sites, and the NKTR-214 overcame resistance to anti-PD-1 in the B2M-KO tumor growth and significantly increased survival.